Management and outcomes of primary anorectal melanoma in the United States

Hari Menon, Roshal R. Patel, Taylor R. Cushman, Arya Amini, Steven N. Seyedin, Anngela C. Adams, Chi Lin, Vivek Verma

Research output: Contribution to journalArticlepeer-review

13 Scopus citations


Aims: To analyze outcomes in primary anorectal melanoma, a rare disease with limited data and treatment guidelines. Materials & methods: We analyzed 305 subjects in the National Cancer Database from 2004 to 2015. The primary end point was overall survival (OS). Results: Surgery was predictive of OS (median 2.24 vs 1.18 years; p = 0.009) with no survival difference between local and transabdominal approaches (p = 0.77). No OS benefit was seen with chemotherapy (p = 0.16), radiotherapy (p = 0.31) or adjuvant therapy post surgery (p > 0.05 for all groups). Targeted therapy trended toward higher survival in metastatic patients (1.33 vs 0.55 years; p = 0.06). Conclusion: In nonmetastatic patients, surgery of any method is associated with a survival benefit. The trend for improved survival following targeted therapy in metastatic patients merits further exploration.

Original languageEnglish (US)
Pages (from-to)329-338
Number of pages10
JournalFuture Oncology
Issue number8
StatePublished - Feb 6 2020


  • abdominoperineal resection
  • local wide excision
  • overall survival
  • surgery
  • targeted therapy

ASJC Scopus subject areas

  • Oncology
  • Cancer Research


Dive into the research topics of 'Management and outcomes of primary anorectal melanoma in the United States'. Together they form a unique fingerprint.

Cite this